What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ZE74-0282 is an oral powder for suspension supplied in 25 mg and 75 mg sachets. It is administered orally with noncarbonated water once daily (QD) or twice daily (BID), as assigned/selected by cohort, in continuous 28-day treatment cycles. Dosing is performed in a fasting state: no food or drink other than water for at least 2 hours before and 1 hour after dosing. The starting dose is 150 mg QD.…”In the company’s words, NCT07529951 on ClinicalTrials.gov
- Tested for
- Polycythemia Vera (PV), Myelofibrosis (MF)
- Main trialPhase 1
- “This first-in-human, randomized, double-blind, placebo-controlled Phase 1 study evaluates the safety, tolerability, and pharmacokinetics of single, split, and multiple oral doses of ZE74-0282 under fasted or fed conditions in healthy adult volunteers.”In the company’s words, NCT07527221 on ClinicalTrials.gov
Other drugs for Polycythemia Vera (PV)
- Givinostat HydrochlorideItalfarmaco · Phase 3
- RusfertideProtagonist Therapeutics, Inc. · Phase 3
- AG-236Agios Pharmaceuticals, Inc. · Phase 2/3
- BomedemstatMerck & Co. · Phase 3
- Ropeginterferon alfa-2bPharmaEssentia · Phase 3
- FlonoltinibChengdu Zenitar Biomedical Technology Co., Ltd · Phase 2
Coming up2
- NovPhase 1 trial completes · ClinicalTrials.gov
- 30 Sep 2028Phase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07529951
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Nov 2026 | Safety and Tolerability of ZE74-0282 in Healthy Volunteers | |
| Phase 1Recruiting | 30 Sep 2028 | Study of ZE74-0282 in Patients With JAK2 V617F- or Calreticulin-Mutated Hematologic Disorders |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026